Chk1/2和Plk1蛋白在宫颈良恶性病变组织中的表达及其意义

The expression of Chk1/2 and Plk1 protein in cervical carcinoma and chronic cervicitis and its significance

背景与目的:Chk1/2(checkpoint kinase 1/2)和Plk1(polo-like kinase 1)是各细胞周期检测点启动DNA损伤修复的主要激酶。本研究主要探讨3种激酶蛋白在宫颈良恶性病变中的表达差异、与宫颈癌临床病理特征的关系及3种激酶在宫颈癌组织中表达之间的相互关系。方法:应用免疫组化SP法检测43例宫颈癌组织和20例慢性宫颈炎性组织中Chk1、Chk2和Plk1蛋白的表达情况。结果:Chk1、Chk2和Plk1蛋白在宫颈癌患者中的阳性率分别为76.7%、60.5%和32.6%,在慢性宫颈炎患者中的阳性率分别为30.0%、35.0%和0;Chk1和Plk1蛋白在宫颈癌组织中的表达显著高于慢性宫颈炎组织(P<0.01),而Chk2的表达差异无显著性(P>0.05)。Chk1、Chk2和Plk1蛋白的表达在不同年龄、病理类型和临床分期的宫颈癌患者中差异无显著性(P>0.05);但Chk1和Plk1的表达在不同分化程度的宫颈癌患者中差异有显著性(P<0.05)。Spearman等级相关分析,在43例宫颈癌患者中,Chk1与Chk2的表达呈正相关(r=0.492,P=0.001)。结论:Chk1和Plk1可能成为比较理想的宫颈癌治疗靶点。

Background and purpose： Chk1/2 （checkpoint kinase 1/2） and Plkl （polo-like kinase 1）played the major role in the regulation of cell cycle when DNA was damaged. The aim of this study was to explore the association of these kinases with clinical pathology parameters of benign cervical lesions, malignant neoplasms and investigate the correlations between each other. Methods： Immunohistochemistry was applied to detect the expressions of Chk1, Chk2 and Plk1 in 43 cases of cervical carcinoma and 20 cases of chronic cervicitis. Results： The positive percentages of Chk1, Chk2 and Plk1 were 76.7%, 60.5% and 32.6% respectively in cervical carcinoma, and compared with 30.0%, 35.0% and 0, respectively in chronic cervicitis; there were statistically significant higher expressions of Chk1 and Plk1 proteins in cervical carcinoma than that in chronic cervicitis （P 〈 0.01） except to Chk2, The expressions of Chk1, Chk2 and Plk1 were not associated with the age, pathology and clinical stage of cervical carcinoma patients （ P 〉 0.05）, while Chk1 and Plkl expressions associated with differentiation of cervical carcinoma （ P 〈0.05）. In 43 cervical carcinoma cases, Chk1 expression was positively correlated with Chk2 expression（r =0.492, P =0. 001）. Conclusions： Chk1 and Plk1 might be the ideal targets for cervical carcinoma therapy.